MedPath

LIVZON PHARMA

🇨🇳China
Ownership
-
Established
1985-01-26
Employees
8.9K
Market Cap
-
Website
http://www.livzon.com.cn
Introduction

The company was founded in January 1985. It is a comprehensive pharmaceutical group company integrating R&D, production and sales of pharmaceutical products, and is an A+H listed company. The company regards R&D innovation as the cornerstone of sustainable development, and continues to pay attention to new molecules and cutting-edge technologies in the global field of new drug research and development. Based on clinical value, differentiated forward-looking layout of innovative drugs and complex formulations with high barriers, the company focuses on the digestive tract, assisted reproduction, psychiatry, tumor immunity, etc., and has formed a complete product cluster and a differentiated product pipeline covering the entire R&D cycle. The company's main business is R&D, production and sales of pharmaceutical products. The main products include iLianan, Rivolol series products, Rebelix, Vitrex, Beiyi, Lisenbao, Lebald, Lifecon, Ripple, Conertin, Shenqi Fuzheng injection, antiviral granules, etc.; mirvastatin, acarbose, colistin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, mirbetaxim and ceftriaxone sodium, etc.; Mycoplasma pneumoniae IgM antibody detection reagents, antibody test reagents for human immunodeficiency Diagnostic reagent products such as kits and antinuclear antibody test kits. Corporate honors: Pearl Delle won the first Grand Prize for Outstanding Contribution to Science and Technology Progress in Zhuhai; Pearl Dole won the Grand Prize for Outstanding Contribution to Promoting Scientific and Technological Progress in Zhuhai; Jinqi Fuzheng Injection won the first prize of the 2006 China Society of Integrative Traditional Chinese and Western Medicine Science and Technology Award, etc.

Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection

Phase 4
Completed
Conditions
Helicobacter Pylori Eradication Antibiotic
Interventions
Drug: Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy
Drug: Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
First Posted Date
2016-07-18
Last Posted Date
2016-07-18
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
100
Registration Number
NCT02835560

Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH

Phase 4
Conditions
Azoospermia
Oligospermia
Interventions
Drug: 75IU uFSH
First Posted Date
2014-12-04
Last Posted Date
2014-12-08
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
180
Registration Number
NCT02307994
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Phase 2
Conditions
Gastroesophageal Reflux Disease
Interventions
First Posted Date
2010-04-21
Last Posted Date
2010-04-21
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
330
Registration Number
NCT01107938

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)

Phase 2
Completed
Conditions
Duodenal Ulcer
Interventions
First Posted Date
2009-08-06
Last Posted Date
2009-08-06
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
235
Registration Number
NCT00953381
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)

Phase 3
Completed
Conditions
Duodenal Ulcer
Interventions
Drug: 10 mg ilaprazole
Drug: 20 mg omeprazole
First Posted Date
2009-08-06
Last Posted Date
2009-08-06
Lead Sponsor
Livzon Pharmaceutical Group Inc.
Target Recruit Count
496
Registration Number
NCT00952978
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath